FDA clears first non-coronary primary use stent
This article was originally published in Clinica
Sulzer IntraTherapeutics has gained US FDA clearance for what it claims is the first peripheral stent to be approved for treating atherosclerosis in the femoral and popliteal arteries in the leg.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.